Holistic Consideration of Patients with Schizophrenia to Improve Medication Adherence and Outcomes
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Although several algorithms have been applied to treat patients with schizophrenia, their clinical use remains still limited, because most emphasize the prescription of antipsychotics. A new algorithm with a more holistic approach to treating patients with schizophrenia, to be used before applying traditional prescribing guidelines, was thus proposed by an expert team of Taiwanese psychiatrists. In this algorithm, several important treatment tasks/modalities are proposed, including long-acting injection antipsychotics, shared decision-making, a case management system, compulsory treatment by law, community rehabilitation programs, the patients’ feeling about their health care professionals (patients’ behaviors) and their attitude/knowledge of their conditions/ illness. This study proposes that evaluating the medication adherence of patients can be determined by two key domains, namely patients’ behaviors and attitudes. Based on different levels of their behaviors (X-axis) and attitude/knowledge (Y-axis), it is possible to categorize patients with schizophrenia into six subgroups, for which various different interventions, including the use of antipsychotics, could be applied and integrated. Further research is needed to assess the applicability of this treatment algorithm in clinical settings.
Abstract
Although several algorithms have been applied to treat patients with schizophrenia, their clinical use remains still limited, because most emphasize the prescription of antipsychotics. A new algorithm with a more holistic approach to treating patients with schizophrenia, to be used before applying traditional prescribing guidelines, was thus proposed by an expert team of Taiwanese psychiatrists. In this algorithm, several important treatment tasks/modalities are proposed, including long-acting injection antipsychotics, shared decision-making, a case management system, compulsory treatment by law, community rehabilitation programs, the patients’ feeling about their health care professionals (patients’ behaviors) and their attitude/knowledge of their conditions/ illness. This study proposes that evaluating the medication adherence of patients can be determined by two key domains, namely patients’ behaviors and attitudes. Based on different levels of their behaviors (X-axis) and attitude/knowledge (Y-axis), it is possible to categorize patients with schizophrenia into six subgroups, for which various different interventions, including the use of antipsychotics, could be applied and integrated. Further research is needed to assess the applicability of this treatment algorithm in clinical settings.
참고문헌 (28)
- Lieberman JA., "Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia", J Clin Psychiatry, 60(Suppl 12), pp.9~12 (1999)
- Molina V., "Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients", Psychiatry Res, 131, pp.45~56 (2004)
- Cahn W., "Brain volume changes in first-episode schizophrenia : a 1-year follow-up study", Arch Gen Psychiatry, 59, pp.1002~1010 (2002)
- Ho BC., "Progressive structural brain abnormalities and their relationship to clinical outcome : a longitudinal magnetic resonance imaging study early in schizophrenia", Arch Gen Psychiatry, 60, pp.585~594 (2003)
- Sun D., "Brain surface contraction mapped in first-episode schizophrenia : a longitudinal magnetic resonance imaging study", Mol Psychiatry, 14, pp.976~986 (2009)
- Emsley R., "The nature of relapse in schizophrenia", BMC Psychiatry, 13, pp.50~ (2013)
- McCreadie RG., "The Scottish first episode schizophrenia study. VIII. Five-year follow-up : Clinical and psychosocial findings", Br J Psychiatry, 161, pp.496~500 (1992)
- Robinson D., "Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder", Arch Gen Psychiatry, 56, pp.241~247 (1999)
- Weiden PJ., "Cost of relapse in schizophrenia", Schizophr Bull, 21, pp.419~429 (1995)
- Thieda P., "An economic review of compliance with medication therapy in the treatment of schizophrenia", Psychiatr Serv, 54, pp.508~516 (2003)
- Zhu B., "Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia", Psychiatr Serv, 59, pp.315~317 (2008)
- Brnabic AJ., "Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia : comparison of matched cohorts from a 12-month observational study", Int J Clin Pract, 65, pp.945~953 (2011)
- Peuskens J., "Treatment retention with risperidone long-acting injection : 24-month results from the Electronic Schizophrenia Treatment Adherence Registry(e-STAR)in six countries", Curr Med Res Opin, 26, pp.501~509 (2010)
- Olivares JM., "Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain : results from the electronic Schizophrenia Treatment Adherence Registry(e-STAR)", Eur Psychiatry, 24, pp.287~296 (2009)
- Tiihonen J., "A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia", Am J Psychiatry, 168, pp.603~609 (2011)
- Ren XS., "Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration", J Clin Pharm Ther, 36, pp.383~389 (2011)
- Heres S., "Attitudes of psychiatrists toward antipsychotic depot medication", J Clin Psychiatry, 67, pp.1948~1953 (2006)
- Patel MX., "Psychiatrists' use, knowledge and attitudes to first-and second-generation antipsychotic long-acting injections : comparisons over 5 years", J Psychopharmacol, 24, pp.1473~1482 (2010)
- Charles C., "Shared decision-making in the medical encounter : what does it mean?(or it takes at least two to tango)", Soc Sci Med, 44, pp.681~692 (1997)
- Hamann J., "Shared decision making in psychiatry", Acta Psychiatr Scand, 107, pp.403~409 (2003)
- Hamann J., "Shared decision making and long-term outcome in schizophrenia treatment", J Clin Psychiatry, 68, pp.992~997 (2007)
- Lehman AF., "Practice guideline for the treatment of patients with schizophrenia, second edition", Am J Psychiatry, 161(2 Suppl), pp.1~56 (2004)
- Hasan A., "World Federation of Societies of Biological Psychiatry(WFSBP)Guidelines for Biological Treatment of Schizophrenia, part 1 : update 2012 on the acute treatment of schizophrenia and the management of treatment resistance", World J Biol Psychiatry, 13, pp.318~378 (2012)
- Hasan A., "World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for biological treatment of schizophrenia, part 2 : update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects", World J Biol Psychiatry, 14, pp.2~44 (2013)
- Argo TR., "Texas medication algorithm project procedural manual : Schizophrenia treatment algorithms" (2008), Texas Department of State Health Services
- Taylor D., "The Maudsley prescribing guidelines. 10th ed" (2009), Informa Healthcare
- Kuipers E., "Psychosis and schizophrenia in adults-The NICE guideline on treatment and management" (2014), National Collaborating Centre for Mental Health, commissioned by the National Institute for Health and Care Excellence
- Chen PS., "Help-seeking behaviors and disease perception in psychiatric patients and their families in a teaching hospital", Chin J Fam Med(Taipei), 12, pp.32~42 (2002)